Vertex Pharmaceuticals will buy Alpine Immune Sciences, a maker of protein-based medicines that harness the immune system, for $4.9 billion, the companies announced Wednesday. It is the largest ...

Vertex Pharmaceuticals VRTX -1.88% has agreed to acquire Alpine Immune Sciences ALPN 0.02% for $4.9 billion in cash, bolstering its portfolio on kidney diseases as deals in biotechnology continue ...

Vertex Pharmaceuticals (NASDAQ:VRTX) has posted new data from a Phase 1/2/3 study for zimislecel (VX-880), its experimental therapy for type 1 diabetes, noting that the cell-based therapy achieved ...

Vertex shares slipped in extended trading Wednesday after the company announced it had agreed to acquire Alpine Immune Sciences for $4.9 billion. The deal values each Alpine share at $65 ...

Vertex Pharmaceuticals is acquiring immune therapies developer Alpine Immune Sciences in a $4.9 billion deal whose centerpiece is a Phase 3-ready drug for a chronic kidney disorder with few ...

Vertex Pharmaceuticals announced its biggest M&A play yet Wednesday evening, acquiring Alpine Immune Sciences for $4.9 billion. The deal was unanimously approved by the board of directors at both ...

Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $65 per share, totaling about $4.9 billion in cash, a 38% premium over Alpine’s ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that three of its researchers have been awarded the 2024 Breakthrough Prize in Life Sciences “for ...

Vertex disputes critics’ allegations of ‘scandalous’ drug pricing By Jonathan Saltzman Globe Staff,Updated April 11, 2024, 6:45 p.m.

Related Beal has landed a full-building lease with Vertex Pharmaceuticals for a seven-story, 344K SF life sciences facility in the Seaport. The project at 22 Drydock Ave. will be the second ...

The rare disease specialist Vertex Pharmaceuticals (VRTX 1.45%) and the molecular cancer diagnostic stalwart Exact Sciences (EXAS -0.38%) are two of the best examples.

Dow Jones Newswires Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion By Ben Glickman Last Updated: April 10, 2024, 5:15 p.m. ET First Published: April 10, 2024, 5:09 p.m ...